Automation in cell and gene therapy manufacturing: from past to future
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
As more and more cell and gene therapies are being developed and with the increasing number of regulatory approvals being obtained, there is an emerging and pressing need for industrial translation. Process efficiency, associated cost drivers and regulatory requirements are issues that need to be addressed before industrialisation of cell and gene therapies can be established. Automation has the potential to address these issues and pave the way towards commercialisation and mass production as it has been the case for ‘classical’ production industries. This review provides an insight into how automation can help address the manufacturing issues arising from the development of large-scale manufacturing processes for modern cell and gene therapy. The existing automated technologies with applicability in cell and gene therapy manufacturing are summarized and evaluated here.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mock, U., Nickolay, L., Philip, B., Cheung, G. W.-K., Zhan, H., Johnston, I. C. D., Kaiser, A. D., Peggs, K., Pule, M., Thrasher, A. J., et al. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.05.009 · Cited by 237
Zhu, F., Shah, N., Xu, H., Schneider, D., Orentas, R., Dropulic, B., Hari, P., & Keever-Taylor, C. A. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2017.09.005 · Cited by 120
Cited by
Scientific, sustainability and regulatory challenges of cultured meat
Post, M. J., Levenberg, S., Kaplan, D. L., Genovese, N., Fu, J., Bryant, C. J., Negowetti, N., Verzijden, K., & Moutsatsou, P. (2020) · Nature Food · doi:10.1038/s43016-020-0112-z · Cited by 783
Self-citationRole of immune cells in the removal of deleterious senescent cells
Kale, A., Sharma, A., Stolzing, A., Desprez, P.-Y., & Campisi, J. (2020) · Immunity & Ageing · doi:10.1186/s12979-020-00187-9 · Cited by 351
ten Ham, R. M. T., Hövels, A. M., Hoekman, J., Frederix, G. W. J., Leufkens, H. G. M., Klungel, O. H., Jedema, I., Veld, S. A. J., Nikolic, T., Van Pel, M., et al. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.03.432 · Cited by 73
“Where possible, the development of modular approaches to CBT manufacturing, exploration of the possibility of allogenic material use instead of or in addition to autologous cells and the multipurposing of existing specialized equipment within the facility could offer opportunities to increase volume throughput [34].”
BackgroundElanzew, A., Nießing, B., Langendoerfer, D., Rippel, O., Piotrowski, T., Schenk, F., Kulik, M., Peitz, M., Breitkreuz, Y., Jung, S., et al. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.580352 · Cited by 47
Self-citationHurdles to uptake of mesenchymal stem cells and their progenitors in therapeutic products
Childs, P. G., Reid, S., Salmeron-Sanchez, M., & Dalby, M. J. (2020) · Biochemical Journal · doi:10.1042/bcj20190382 · Cited by 27
Metadata
- Authors
- Moutsatsou, P., Ochs, J., Schmitt, R. H., Hewitt, C. J., & Hanga, M. P.
- Venue
- Biotechnology Letters
- Published
- 2019-09-20
- Volume
- 41
- Issue
- 11
- Pages
- 1245-1253
- ISSN
- 0141-5492 (ISSN-L)
- 1573-6776
- OpenAlex
- W2974070007
- Cited by
- 110
- References
- 2
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Automation in cell and gene therapy manufacturing: from past to future. https://app.cochat.ai/papers/10.1007/s10529-019-02732-z
- The paper
- Moutsatsou, P., Ochs, J., Schmitt, R. H., Hewitt, C. J., & Hanga, M. P. (2019). Automation in cell and gene therapy manufacturing: from past to future. Biotechnology Letters. https://doi.org/10.1007/s10529-019-02732-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.